Health & Life Sciences Rx Podcast - Episode 9

Episode 9: Choosing the Right Biotech Exit Strategy

M&A activity has remained healthy in the biotech sector, as big pharma looks to scoop up the next blockbuster drug, and appetite for gene and immune oncology therapies continues to skyrocket. But when given the choice between an offer from a potential buyer, or the long road to commercialization, biotech companies must ask themselves: Do I stay the course or is now the right time to exit?
 
In this episode of BDO’s Health & Life Sciences Rx Podcast, BDO’s Todd Berry sits down with leaders from Universal Cells, Fortress Biotech, and McDermott Will & Emery to discuss how leaders in biotech can assess the current M&A and IPO landscape to choose the right exit strategy for their organization.

Tune in for insights into:

• How to assess if it’s the right time to exit and what to look for in a potential partner
• Emerging areas in biotech where future investment and deal flow is likely to increase
• Why drug pricing policy is keeping biotech leaders up at night